Biosimilar granulocyte–colony‐stimulating factor for healthy donor stem cell mobilization: need we be afraid?
Authors:
Open Access
- 26 June 2014
- journal article
- review article
- Published by Wiley in Transfusion
- Vol. 55 (2) , 430-439
Abstract
Biosimilars are approved biologics with comparable quality, safety, and efficacy to a reference product. Unlike generics, which are chemically manufactured copies of small‐molecule drugs with relatively simple chemical structures, the biosimilar designation is applied to drugs that are produced by living organisms, implying much more difficult to control manufacturing and purification procedures. To account for these complexities, the European Medicines Agency (EMA), the US Food and Drug Administration, the Australian Therapeutic Goods Administration, and other regulatory authorities have devised and implemented specific, markedly more demanding pathways for the evaluation and approval of biosimilars. To date, several biosimilars have been approved, including versions of somatropin, erythropoietin, and granulocyte–colony‐stimulating factor (G‐CSF), and several biosimilar monoclonal antibodies are currently in development. The reference G‐CSF product (Neupogen, Amgen) has been used for many years for prevention and treatment of neutropenia and also for mobilization of peripheral blood stem cells (PBSCs). However, concerns have been raised about the safety and efficacy of biosimilar G‐CSF during PBSC mobilization procedures, especially in healthy donors. This article reviews the available evidence on the use of biosimilar G‐CSF in this setting. Aggregate clinical evidence supports the assessment by the EMA of biosimilar and originator G‐CSF as highly biologically similar, with respect to desired and undesired effects.Keywords
This publication has 53 references indexed in Scilit:
- Clinical experience with Zarzio® in Europe: what have we learned?Supportive Care in Cancer, 2013
- G-CSF in Healthy Allogeneic Stem Cell DonorsTransfusion Medicine and Hemotherapy, 2013
- The Continuum of Comparability Extends to Biosimilarity: How Much Is Enough and What Clinical Data Are Necessary?Clinical Pharmacology & Therapeutics, 2013
- Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donorsBone Marrow Transplantation, 2013
- Critical appraisal of biosimilar filgrastim (Nivestim™) for febrile and chemotherapy-induced neutropeniaBiosimilars, 2012
- First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factorAdvances in Therapy, 2011
- Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donorsBlood, 2009
- Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor ProgramBlood, 2009
- Biosimilar therapeutics--what do we need to consider?NDT Plus, 2009
- XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapyBMC Cancer, 2008